Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Open access

Abstract

BACKGROUND Spasticity is a major determinant of disability and decline in quality of life in patients with motor neuron disease. Cannabinoids have been approved for symptomatic treatment of spasticity in multiple sclerosis. We investigated whether cannabinoids might also reduce spasticity in patients with motor neuron disease. METHODS We did an investigator-initiated, randomised, double-blind, placebo-controlled, phase 2 clinical trial at four tertiary motor neuron disease centres in Italy. Eligible patients were aged 18-80 years; had possible, laboratory-supported probable, probable, or definite amyotrophic lateral sclerosis as defined by revised El Escorial criteria, or primary lateral sclerosis according to Pringle's criteria; had spasticity symptoms due to motor neuron disease for at least 3 months; had spasticity scores of 1 or greater in at least two muscle groups on the Modified Ashworth Scale; and were taking an antispasticity regimen that was maintained at a stable dose for 30 days before enrolment. Participants were assigned (1:1) by an independent statistician via a computer-generated randomisation sequence to a standardised oromucosal spray (nabiximols) containing a defined combination of delta-9-tetrahydrocannabinol and cannabidiol (each 100 μL actuation contained 2·7 mg delta-9-tetrahydrocannabinol and 2·5 mg cannabidiol) or to placebo for 6 weeks. Participants self-titrated during the first 14 treatment days according to a predefined escalation scheme (maximum…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30406-x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 41 references

Cited by

See all 106

Metadata

Authors
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., Quattrini, A., Pieri, E., Marinou, K., Querin, G., Sansone, V., Maestri, E., Calvo, A., & Chio, A.
Affiliations
  • Vita-Salute San Raffaele University (IT)
  • Istituti Clinici Scientifici Maugeri (IT)
  • University of Pavia (IT)
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2019-02
Volume
18
Issue
2
Pages
155-164
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2905561928
Cited by
104
References
41
Citations by year
2026: 8 · 2025: 7 · 2024: 22 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 12 · 2019: 7
FWCI
6.27
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, other-oa)
Funders
  • GW Pharmaceuticals
  • Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica
Topics
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
nabiximols, cannabinoids, spasticity, motor neuron disease, amyotrophic lateral sclerosis, primary lateral sclerosis, oromucosal spray, delta-9-tetrahydrocannabinol, cannabidiol, Modified Ashworth Scale, drug safety and tolerability, self-titration, quality of life, disability progression, neuromodulation
MeSH terms
Adult, Aged, Cannabidiol, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Muscle Spasticity, Quality of Life, Dronabinol, Motor Neuron Disease, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30406-x
The paper
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., . . . Chio, A. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30406-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.